4D pharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of 4D pharma generated cash of -$37,916,000, which is less than the previous year. Cash used in financing activities reached the amount of $46,418,000 last year. Net change in cash is therefore $8,983,000.
Cash Flow
| 2014 | -3.81M | -4.01M | 36.65M |
|---|---|---|---|
| 2015 | -9.07M | -81.74M | 63.77M |
| 2016 | -13.52M | 40.41M | 0 |
| 2017 | -17.19M | 408K | -14K |
| 2018 | -22.93M | 27.13M | -11K |
| 2019 | -21.55M | 9.71M | -377K |
| 2020 | -22.67M | -178K | 27.79M |
| 2021 | -37.91M | -279K | 46.41M |
LBPS Cash Flow Statement (2014 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 11.99M | 3.83M | 16.05M | 11.86M | 28.66M | 1.77M | 28.82M | 0 |
Operating activities | ||||||||
Net income | -31.93M | -25.96M | -24.06M | -23.69M | -20.44M | -9.86M | -7.54M | -2.02M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 1.35M | 1.20M | 1.28M | 1.20M | 982K | 618K | 253K | 114K |
Stock-based compensation expense | 711K | 3.33M | 267K | 268K | 302K | 131K | 7K | 0 |
| Deferred income tax benefit | 711K | 3.33M | 267K | 268K | 302K | 131K | 7K | 0 |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 25.64K | -93K | 92K | -37K | -15K | -210K | 87K | -115K |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -37.91M | -22.67M | -21.55M | -22.93M | -17.19M | -13.52M | -9.07M | -3.81M |
Investing activities | ||||||||
Purchases Of Investments | 0 | 0 | 0 | 4K | 0 | 76K | -80.65M | -3.00M |
Investments In Property Plant And Equipment | -279K | -178K | -595K | -541K | -2.07M | -2.31M | -859K | -264K |
Acquisitions Net | 0 | 0 | 0 | -660K | 0 | -1.61M | -402K | 238K |
Cash generated by investing activities | -279K | -178K | 9.71M | 27.13M | 408K | 40.41M | -81.74M | -4.01M |
Financing activities | ||||||||
Common Stock Issued | 24.84M | 29.74M | 0 | 0 | 0 | 0 | 64.75M | 38.1M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -500K |
Cash used in financing activities | 46.41M | 27.79M | -377K | -11K | -14K | 0 | 63.77M | 36.65M |
Net Change In Cash | 8.98M | 4.93M | -12.21M | 4.18M | -16.79M | 26.88M | -27.04M | 28.82M |
Cash at end of period | 20.97M | 8.77M | 3.83M | 16.05M | 11.86M | 28.66M | 1.77M | 28.82M |
| Data source | Data source | Data source | Data source | Data source |